近年来,国产RET抑制剂正在不断涌现,除了信达生物和基石药业授权引进塞普替尼和普拉替尼已经获批上市外,还有多款产品已先后在国内申请上市,包括科伦博泰的仑博替尼(A400/EP0031)、首药控股的索特替尼(SY-5007)、翰森制药的瑞森替尼(HS-10365)等,申报的适应症均为RET融合阳性的局部晚期或转移性成人非小细胞肺癌(NSCLC)。其中,根据资料显示,仑博替尼是科伦博泰自主研发的二代小...
Source Link近年来,国产RET抑制剂正在不断涌现,除了信达生物和基石药业授权引进塞普替尼和普拉替尼已经获批上市外,还有多款产品已先后在国内申请上市,包括科伦博泰的仑博替尼(A400/EP0031)、首药控股的索特替尼(SY-5007)、翰森制药的瑞森替尼(HS-10365)等,申报的适应症均为RET融合阳性的局部晚期或转移性成人非小细胞肺癌(NSCLC)。其中,根据资料显示,仑博替尼是科伦博泰自主研发的二代小...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.